This statistic shows the cost to bring biopharmaceutical asset to market among mid-cap biopharma companies in 2010, 2016, 2017, 2018, and 2019. According to the data, in 2017, the cost to bring an asset to market was around 2.17 billion U.S. dollars.
Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies in 2010, 2016, 2017, 2018, and 2019
(in billion U.S. dollars)
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Single Account
Your perfect start with Statista
Instant access to 1m statistics
Download in XLS, PDF & PNG format
Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
Deloitte, & GlobalData. (December 10, 2019). Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies in 2010, 2016, 2017, 2018, and 2019 (in billion U.S. dollars) [Graph]. In Statista. Retrieved April 02, 2020, from https://www.statista.com/statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
Deloitte, und GlobalData. "Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies in 2010, 2016, 2017, 2018, and 2019 (in billion U.S. dollars)." Chart. December 10, 2019. Statista. Accessed April 02, 2020. https://www.statista.com/statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
Deloitte, GlobalData. (2019). Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies in 2010, 2016, 2017, 2018, and 2019 (in billion U.S. dollars). Statista. Statista Inc.. Accessed: April 02, 2020. https://www.statista.com/statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
Deloitte, and GlobalData. "Average Cost to Bring a Pharmaceutical Asset to Market among mid Cap Biopharma Companies in 2010, 2016, 2017, 2018, and 2019 (in Billion U.S. Dollars)." Statista, Statista Inc., 10 Dec 2019, https://www.statista.com/statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
Deloitte & GlobalData, Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies in 2010, 2016, 2017, 2018, and 2019 (in billion U.S. dollars) Statista, https://www.statista.com/statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/ (last visited April 02, 2020)
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.
